Send me a link:

*Only U.S. numbers are accepted. Text messaging rates may apply.

 Dow Up0.55% Nasdaq Up0.29%

TG Therapeutics, Inc. (TGTX)

5.33 0.16(2.91%) Apr 15, 4:00PM EDT
Get the big picture on all your investments.
ProfileGet Profile for:
TG Therapeutics, Inc.
3 Columbus Circle
15th Floor
New York, NY 10019
United States - Map
Phone: 212-554-4484
Fax: 212-554-4531

Index Membership:N/A
Full Time Employees:13

Business Summary 

TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of various pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The company is developing two therapies targeting hematological malignancies. Its therapies include TG-1101, a chimeric glycoengineered monoclonal antibody that targets a unique epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TGR-1202, an orally available phosphoinositide-3-kinase delta inhibitor with nanomolar potency. The company is based in New York, New York.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on TG Therapeutics, Inc.

Corporate Governance 
TG Therapeutics, Inc.’s ISS Governance QuickScore as of Apr 1, 2014 is 7. The pillar scores are Audit: 10; Board: 9; Shareholder Rights: 2; Compensation: 8.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Mr. Michael S. Weiss Esq., 48
Exec. Chairman, Interim Chief Exec. Officer and Pres
Mr. Sean A. Power CPA, 32
Chief Financial Officer, Principal Accounting Officer, Treasurer and Sec.
Dr. Robert Niecestro Ph.D.,
Exec. VP of Clinical and Regulatory
Amounts are as of Dec 31, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders